Display options
Cite
Assarzadegan F, Tabesh H, Hosseini-Zijoud SM, et al. Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety. Iran Red Crescent Med J. 2016;18(9):e23768doi: 10.5812/ircmj.23768.
Assarzadegan, F., Tabesh, H., Hosseini-Zijoud, S. M., Beale, A. D., Shoghli, A., Ghafoori Yazdi, M., Mansouri, B., Hesami, O., Beladi Moghadam, N., & Delavar Kasmaei, H. (2016). Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety. Iranian Red Crescent medical journal, 18(9), e23768. https://doi.org/10.5812/ircmj.23768
Assarzadegan, Farhad, et al. "Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety." Iranian Red Crescent medical journal vol. 18,9 (2016): e23768. doi: https://doi.org/10.5812/ircmj.23768
Assarzadegan F, Tabesh H, Hosseini-Zijoud SM, Beale AD, Shoghli A, Ghafoori Yazdi M, Mansouri B, Hesami O, Beladi Moghadam N, Delavar Kasmaei H. Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety. Iran Red Crescent Med J. 2016 Apr 30;18(9):e23768. doi: 10.5812/ircmj.23768. eCollection 2016 Sep. PMID: 28144450; PMCID: PMC5253208.
Copy Download .nbib Format: NLM
Share it on

Iran Red Crescent Med J. 2016 Apr 30;18(9):e23768. doi: 10.5812/ircmj.23768. eCollection 2016 Sep.

Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety.

Iranian Red Crescent medical journal

Farhad Assarzadegan, Hanif Tabesh, Seyed-Mostafa Hosseini-Zijoud, Andrew David Beale, Arya Shoghli, Mahmood Ghafoori Yazdi, Behnam Mansouri, Omid Hesami, Nahid Beladi Moghadam, Hosein Delavar Kasmaei

Affiliations

  1. Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
  2. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
  3. Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
  4. Research Complex at Harwell, London, United Kingdom.
  5. Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.

PMID: 28144450 PMCID: PMC5253208 DOI: 10.5812/ircmj.23768

Abstract

BACKGROUND: Migraine is one of the most debilitating medical conditions and has a high socioeconomic burden. As conventional therapeutic methods do not entirely alleviate the symptoms, new alternatives are being considered.

OBJECTIVES: This study evaluates the efficacy and safety of zonisamide compared with sodium valproate in the management of migraine headaches.

PATIENTS AND METHODS: In the current double-blind, parallel, randomized, controlled trial, 96 patients with a migraine diagnosis based on the international headache society (HIS) criteria were selected. They were divided randomly into two groups; the case group was given zonisamide, and sodium valproate was given to a control group. In addition to the side effects of the drugs, the severity, duration, and frequency of migraine attacks were evaluated at baseline and at three months.

RESULTS: The 96 selected patients were divided randomly into two treatment groups (zonisamide n = 48, sodium valproate n = 48). Seven patients were excluded from analysis because of early dropout, leaving 89 (n = 45; n = 44) patients for analysis. While using zonisamide, six (13%) patients complained of fatigue, and two (4%) patients encountered noticeable appetite and weight loss. In the control group, five (11%) patients reported dizziness, and four (9%) patients faced obvious appetite and weight gain. Both drugs were considerably efficient in reducing further attacks. There was no statistically significant correlation between frequency or severity of migraine attacks and the drug used for treatment in three months of follow-up.

CONCLUSIONS: Both medications are effective in reducing migraine attacks. It will be important to consider the drugs' adverse effects and availability and patients' medical and socioeconomic condition to select the appropriate treatment.

Keywords: Migraine Headaches; RCT; Sodium Valproate; Zonisamide

References

  1. Cephalalgia. 2010 Sep;30(9):1065-72 - PubMed
  2. Epileptic Disord. 2013 Sep;15(3):278-88 - PubMed
  3. Epilepsia. 2004 Aug;45(8):924-7 - PubMed
  4. Nihon Hinyokika Gakkai Zasshi. 2013 Sep;104(5):674-7 - PubMed
  5. Neuropsychiatr Dis Treat. 2008 Jun;4(3):535-48 - PubMed
  6. Headache. 2006 May;46(5):804-7 - PubMed
  7. Saudi Pharm J. 2012 Jan;20(1):1-7 - PubMed
  8. Neurology. 2013 Sep 10;81(11):948-55 - PubMed
  9. Expert Rev Clin Pharmacol. 2014 Mar;7(2):191-201 - PubMed
  10. Arch Pediatr. 2008 Nov;15(11):1693-9 - PubMed
  11. Epilepsy Behav. 2013 Nov;29(2):281-4 - PubMed
  12. Clin Neuropharmacol. 2009 Mar-Apr;32(2):103-6 - PubMed
  13. Curr Treat Options Neurol. 2001 May;3(3):257-270 - PubMed
  14. Clin Neuropharmacol. 2004 Nov-Dec;27(6):278-80 - PubMed
  15. J Headache Pain. 2012 Mar;13(2):147-57 - PubMed
  16. Cephalalgia. 2006 Oct;26(10):1199-202 - PubMed
  17. Br Med J. 1974 Jun 15;2(5919):584-6 - PubMed
  18. Intern Med. 2010;49(5):409-13 - PubMed

Publication Types